{
    "organizations": [],
    "uuid": "2b775715a6e148b7441df9a1f59fd34bdab496a2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-mannkind-opens-enrollment-of-phase/brief-mannkind-opens-enrollment-of-phase-1-trial-of-treprostinil-technosphere-idUSASB0C8FZ",
    "ord_in_thread": 0,
    "title": "BRIEF-MannKind Opens Enrollment Of Phase 1 Trial Of Treprostinil Technosphere",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 1 (Reuters) - Mannkind Corp:\n* MANNKIND OPENS ENROLLMENT OF PHASE 1 TRIAL OF TREPROSTINIL TECHNOSPHERE FOR PULMONARY ARTERIAL HYPERTENSION\n* MANNKIND - IF SUCCESSFUL, PHASE 1 STUDY OF TREPROSTINIL TECHNOSPHERE FOR PULMONARY ARTERIAL HYPERTENSION WILL LEAD TO REGISTRATION STUDIES IN 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-02T05:07:00.000+02:00",
    "crawled": "2018-03-01T23:23:20.013+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "mannkind",
        "corp",
        "mannkind",
        "open",
        "enrollment",
        "phase",
        "trial",
        "treprostinil",
        "technosphere",
        "pulmonary",
        "arterial",
        "hypertension",
        "mannkind",
        "successful",
        "phase",
        "study",
        "treprostinil",
        "technosphere",
        "pulmonary",
        "arterial",
        "hypertension",
        "lead",
        "registration",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}